神奇制药
(600613)
| 流通市值：32.31亿 | | | 总市值：36.00亿 |
| 流通股本：4.79亿 | | | 总股本：5.34亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 960,849,846.72 | 479,926,834.64 | 2,048,808,450.63 | 1,563,273,519.07 |
| 营业收入 | 960,849,846.72 | 479,926,834.64 | 2,048,808,450.63 | 1,563,273,519.07 |
| 二、营业总成本 | 903,529,215.25 | 455,826,488.73 | 1,924,744,427.86 | 1,481,112,830.96 |
| 营业成本 | 510,774,959.81 | 255,467,264.82 | 1,075,066,712.95 | 799,209,934.66 |
| 税金及附加 | 14,474,919.24 | 9,244,630.85 | 26,914,343 | 21,906,440.35 |
| 销售费用 | 317,994,848.64 | 160,128,803.18 | 692,354,425.88 | 559,647,311.54 |
| 管理费用 | 44,994,683.6 | 21,910,380.2 | 92,654,588.47 | 66,570,448.65 |
| 研发费用 | 13,850,931.65 | 7,656,280.53 | 32,885,108.76 | 31,895,111.13 |
| 财务费用 | 1,438,872.31 | 1,419,129.15 | 4,869,248.8 | 1,883,584.63 |
| 其中:利息费用 | 5,104,956.55 | 2,484,396.81 | 12,796,063.86 | 8,766,698.93 |
| 其中:利息收入 | 4,097,106.48 | 1,164,121.02 | 9,595,175.98 | 6,927,613.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 151,126.36 | 223,655.42 | -23,908.42 | -306,263.98 |
| 加:投资收益 | - | - | 1,258,491.64 | 797,136.97 |
| 资产处置收益 | - | - | -119,331.4 | 159,663.56 |
| 资产减值损失(新) | -8,017,259.23 | -558,121.75 | -23,119,643.24 | -963,504.41 |
| 信用减值损失(新) | -5,968,578.48 | -3,910,182.42 | -15,839,065.25 | -11,418,386.47 |
| 其他收益 | 2,651,717.94 | 1,026,272.45 | 5,446,524.41 | 3,892,837.07 |
| 四、营业利润 | 46,137,638.06 | 20,881,969.61 | 91,667,090.51 | 74,322,170.85 |
| 加:营业外收入 | 70,005.42 | 5,114.02 | 256,771.77 | 644,750.04 |
| 减:营业外支出 | 752,919.55 | 733,929.94 | 4,345,995.61 | 2,755,865.41 |
| 五、利润总额 | 45,454,723.93 | 20,153,153.69 | 87,577,866.67 | 72,211,055.48 |
| 减:所得税费用 | 11,040,218.48 | 4,435,580.39 | 21,499,804.47 | 13,396,898.52 |
| 六、净利润 | 34,414,505.45 | 15,717,573.3 | 66,078,062.2 | 58,814,156.96 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 34,414,505.45 | 15,717,573.3 | 66,078,062.2 | 58,814,156.96 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 32,808,146.86 | 14,994,496.83 | 71,388,047.35 | 59,353,789.97 |
| 少数股东损益 | 1,606,358.59 | 723,076.47 | -5,309,985.15 | -539,633.01 |
| 扣除非经常损益后的净利润 | 31,976,889.64 | 14,991,554.03 | 71,121,491.2 | 57,475,381.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.03 | 0.13 | 0.11 |
| (二)稀释每股收益 | 0.06 | 0.03 | 0.13 | 0.11 |
| 八、其他综合收益 | -3,417,692.18 | -4,370,158.26 | 9,670,419.82 | 13,352,966.11 |
| 归属于母公司股东的其他综合收益 | -3,417,692.18 | -4,370,158.26 | 9,670,419.82 | 13,352,966.11 |
| 九、综合收益总额 | 30,996,813.27 | 11,347,415.04 | 75,748,482.02 | 72,167,123.07 |
| 归属于母公司股东的综合收益总额 | 29,390,454.68 | 10,624,338.57 | 81,058,467.17 | 72,706,756.08 |
| 归属于少数股东的综合收益总额 | 1,606,358.59 | 723,076.47 | -5,309,985.15 | -539,633.01 |
| 公告日期 | 2025-08-30 | 2025-04-26 | 2025-04-26 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |